Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 DDI with Clopidogrel and Clarithromycin
NCT07040787Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-5965 in Complement 3 glomerulopathy (C3G) and Hemolytic anemia (HA) (2 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration. Started Jul 2025; status: completed.
02
Drugs
HRS-5965
03
Conditions
Complement 3 glomerulopathy (C3G)Hemolytic anemia (HA)
Beyond the preview
Go deeper on NCT07040787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040787.